Compare JUBILANT LIFE SCIENCES with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES CIPLA JUBILANT LIFE SCIENCES/
CIPLA
 
P/E (TTM) x 13.3 22.1 60.4% View Chart
P/BV x 1.7 2.4 68.8% View Chart
Dividend Yield % 0.9 0.7 134.7%  

Financials

 JUBILANT LIFE SCIENCES   CIPLA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
CIPLA
Mar-19
JUBILANT LIFE SCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs898678 132.4%   
Low Rs618484 127.6%   
Sales per share (Unadj.) Rs572.0198.2 288.6%  
Earnings per share (Unadj.) Rs36.218.5 195.6%  
Cash flow per share (Unadj.) Rs59.535.0 170.1%  
Dividends per share (Unadj.) Rs4.503.00 150.0%  
Dividend yield (eoy) %0.60.5 115.0%  
Book value per share (Unadj.) Rs301.9186.3 162.0%  
Shares outstanding (eoy) m159.28805.70 19.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.9 45.2%   
Avg P/E ratio x20.931.4 66.7%  
P/CF ratio (eoy) x12.716.6 76.7%  
Price / Book Value ratio x2.53.1 80.5%  
Dividend payout %12.416.2 76.7%   
Avg Mkt Cap Rs m120,694468,031 25.8%   
No. of employees `0002.422.6 10.6%   
Total wages/salary Rs m19,26028,565 67.4%   
Avg. sales/employee Rs Th38,120.67,053.1 540.5%   
Avg. wages/employee Rs Th8,058.41,261.5 638.8%   
Avg. net profit/employee Rs Th2,414.3659.1 366.3%   
INCOME DATA
Net Sales Rs m91,108159,710 57.0%  
Other income Rs m3574,766 7.5%   
Total revenues Rs m91,466164,475 55.6%   
Gross profit Rs m17,39030,973 56.1%  
Depreciation Rs m3,70913,263 28.0%   
Interest Rs m2,1981,684 130.5%   
Profit before tax Rs m11,84020,791 56.9%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2685,695 57.4%   
Profit after tax Rs m5,77014,924 38.7%  
Gross profit margin %19.119.4 98.4%  
Effective tax rate %27.627.4 100.8%   
Net profit margin %6.39.3 67.8%  
BALANCE SHEET DATA
Current assets Rs m45,848124,266 36.9%   
Current liabilities Rs m20,89737,715 55.4%   
Net working cap to sales %27.454.2 50.5%  
Current ratio x2.23.3 66.6%  
Inventory Days Days5791 62.7%  
Debtors Days Days5195 53.7%  
Net fixed assets Rs m65,498105,190 62.3%   
Share capital Rs m1591,611 9.9%   
"Free" reserves Rs m47,930148,511 32.3%   
Net worth Rs m48,089150,123 32.0%   
Long term debt Rs m42,42938,301 110.8%   
Total assets Rs m114,685239,633 47.9%  
Interest coverage x6.413.3 47.9%   
Debt to equity ratio x0.90.3 345.8%  
Sales to assets ratio x0.80.7 119.2%   
Return on assets %6.96.9 100.2%  
Return on equity %12.09.9 120.7%  
Return on capital %12.411.8 104.9%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,42257,410 21.6%   
Fx outflow Rs m17,22719,041 90.5%   
Net fx Rs m-4,80538,368 -12.5%   
CASH FLOW
From Operations Rs m11,21516,911 66.3%  
From Investments Rs m-10,118-16,687 60.6%  
From Financial Activity Rs m6,574-3,487 -188.5%  
Net Cashflow Rs m7,612-3,451 -220.6%  

Share Holding

Indian Promoters % 45.6 16.0 285.0%  
Foreign collaborators % 3.5 20.8 16.8%  
Indian inst/Mut Fund % 8.7 12.2 71.3%  
FIIs % 21.2 23.7 89.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 21.1 26.2 80.5%  
Shareholders   23,815 161,166 14.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Nov 14, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS